Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
@article{Barragn2008MinimalRD,
title={Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.},
author={Eva Barrag{\'a}n and Juan Carlos Pajuelo and Sandra Ballester and Oscar Fuster and Jos{\'e} D{\'i}az Cervera and F. Moscard{\'o} and Leonor Senent and Esperanza Such and Miguel Angel Sanz and Pascual Bolufer},
journal={Clinica chimica acta; international journal of clinical chemistry},
year={2008},
volume={395 1-2},
pages={120-3}
}- Published 2008 in Clinica chimica acta; international journal of…
DOI:10.1016/j.cca.2008.05.021
BACKGROUND
Molecular analysis of minimal residual disease is only applicable in acute myeloblastic leukemia (AML) patients with genetic markers (20-30%). This study analyzes the feasibility of the real-time quantitative polymerase chain reaction (RQ-PCR) assay to detect mutant nucleophosmin (NPM1) during follow-up in AML patients. Moreover, we compare the NPM1 results with those of WT1 expression to MRD assessment.
METHODS
The study includes 97 samples from 24 AML patients with type A NPM1… CONTINUE READING